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Background: To report technical features, early outcome and toxicity of stereotactic body radiation therapy (SBRT)
treatments with volumetric modulated arc therapy (RapidArc) for patients with hepatocellular carcinoma (HCC).
Methods: Twenty patients (22 lesions) were prospectively enrolled in a feasibility study. Dose prescription was 50Gy
in 10 fractions. Seven patients (35%) were classified as AJCC stage I-II while 13 (65%) were stages III-IV. Eighteen
patients (90%) were Child-Pugh stage A, the remaining were stage B. All patients were treated with RapidArc
technique with flattening filter free (FFF) photon beams of 10MV from a TrueBeam linear accelerator. Technical,
dosimetric and early clinical assessment was performed to characterize treatment and its potential outcome.
Results: Median age was 68 years, median initial tumor volume was 124 cm3 (range: 6–848). Median follow-up time
was 7.4 months (range: 3–13). All patients completed treatment without interruption. Mean actuarial overall survival
was of 9.6 ± 0.9 months (95%C.L. 7.8-11.4), median survival was not reached; complete response was observed in
8/22 (36.4%) lesions; partial response in 7/22 (31.8%), stable disease in 6/22 (27.3%), 1/22 (4.4%) showed progression.
Toxicity was mild with only 1 case of grade 3 RILD and all other types were not greater than grade 2. Concerning
dosimetric data, Paddick conformity index was 0.98 ± 0.02; gradient index was 3.82 ± 0.93; V95% to the clinical target
volume was 93.6 ± 7.7%. Mean dose to kidneys resulted lower than 3.0Gy; mean dose to stomach 4.5 ± 3.0Gy; D1cm
3
to spinal cord was 8.2 ± 4.5Gy; D1% to the esophagus was 10.2 ± 9.7Gy. Average beam on time resulted 0.7 ± 0.2
minutes (range: 0.4-1.4) with the delivery of an average of 4.4 partial arcs (range: 3–6) of those 86% non-coplanar.
Conclusions: Clinical results could suggest to introduce VMAT-RapidArc as an appropriate SBRT technique for
patients with HCC in view of a prospective dose escalation trial.
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Hepatocellular carcinoma (HCC) is the third cause of can-
cer death and one of the most challenging oncological
problems [1]. Several treatment techniques, including
surgery, transcatheter arterial chemoembolization, ra-
diofrequency ablation, percutaneous ethanol injection,
chemotherapy and targeted agents have been explored* Correspondence: lucozzi@iosi.ch
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stated.with complex decision trees and limited impact on
outcome [2-6].
Conventional radiotherapy was offered to HCC patients
in the past but it was limited by severe radiation induced
liver disease (RILD) when excessive fractions of the liver
were involved in the radiation field [7] and the important
relationship between the volume of irradiated normal liver
and the toxicity profile [8,9]. Recently, volumetric modu-
lated arc therapy (VMAT) was explored in the frame of in-
vestigating the role of intensity modulation with rotational
techniques. Our previous studies [10,11] reported abouttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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survival rates around 80-100% and 60-100% for stage I-II
patients, respectively.
Stereotactic body radiation therapy (SBRT) approaches
have been hypothesized for smaller target and in cases
requiring modest irradiation of entire liver (less than
1/4 of the volume). Tse et al. [12] reported on a phase-I
liver cancer dose-escalation trial which included 31 HCC
patients. With a median dose 36 Gy in 6 fractions, they
achieved a 12 month local control rate of 65%. Overall
survival was 48% at one-year. Kwon et al. [13] reported
about 42 HCC patients treated with a median dose of
33 Gy in 3 fractions and a local control of 72 and 67.5% at
1 and 2 years, respectively. Consistent with other SBRT
studies, their result had very low toxicity (less than 2%)
and low incidence of RILD (2%). Andolino et al. [14] sum-
marized the treatment results of 60 patients, Child-Pugh
(CP) stage A, received 30–48 Gy in 3 fractions. Local
control was 93% at 1-year with a 1-year overall survival
of 93% (77% at 2 years). CP stage B patients received
24–48 Gy in 3 fractions with a relative lower survival
(70% at 1 year). Bujold et al. [15], from a cohort of 102
patients treated in two sequential trials between 2004
and 2010, showed a 1 year local control of 87% with a clear
association of better outcome with higher SBRT doses,
although the toxicity higher than grade 3 was observed
in one third of the patients (a severe possibly treatment
related fatalities were observed as well). Klein and Dawson [16]
concluded that SBRT in HCC can have comparable re-
sults with other therapies and suggested that it might
be offered as an treatment option for early stage HCC
patients or patients not eligible to other ablative procedures
for any reason.
In general, there is still no systematic large scale trial
performed to assess i) best treatment modality for SBRT
from technical point of view and ii) maximum tolerable
dose in absence of severe complications. In this frame,
the present study assessed as a first step on a group of
prospectively treated patients, the feasibility of a moder-
ate SBRT regimen delivering 50Gy in 10 fractions with
RapidArc using high intensity photon beams (flattening
filter free (FFF) beams). Scope was to determine the feasi-
bility and the safety of the treatment as a preliminary
component to a formal dose escalation trial to be started
at the home institute with a more aggressive fractionation
scheme (3 fractions with dose levels from 12Gy up to




Starting from September 2012, 20 HCC patients presented
with Barcelona Clinic Liver Cancer (BCLC) stage A to C
(one stage 0) and CP stages A-B with single or doublelesions (preferably with tumor size >5 cm or because of
the poor liver reserves) were eligible for SBRT with
moderate hypofractionation and were enrolled in a
prospective feasibility study at the home institute. The
institute’s ethical committee approved the protocol. All
patients received radiotherapy as primary treatment and
at least 30 elapsed days after any prior treatment. Portal
vein thrombosis was present in six (35%) patients. Relative
contraindication to inclusion were: total bilirubin levels
greater than 3 to 5 mg/dL; white blood count (WBC) less
than 2500–1500 U/dL; Glutamic pyruvic transaminase
(GPT) in the range of 100–300 U/L. Absolute exclusion
criteria included total bilirubin >5 mg/dL, WBC < 1500
U/dL and GPT > 300 U/L. Patients violating relative con-
traindications were enrolled on a case-by-case based on
medical decision.
Radiation treatment
Dose prescription was of 50Gy in 10 fractions, 5Gy/fraction
(this is the lower level dose prescription in a risk adapted
scheme; lesion with a size between 3 and 5 cm would re-
ceive 8-12Gy x 5 fractions and patients with lesions <3 cm
would be treated with 15-25Gy x 3 fractions; all depending
on tumor location and normal tissue tolerance). Plans were
designed for single course treatments. The gross tumor
volume (GTV) was defined as the primary tumor plus
abnormal portal areas revealed on 4 dimensional gated
computerized tomography (4D-CT) images, intravenous
contrast medium administration for enhancement was
used for all patients, except for those patients with renal
dysfunction, Magnetic resonance image (MRI) was added
and fused to planning CT for more precise target delinea-
tion. The clinical target volume (CTV) was defined as the
GTV. For all patients, an internal target volume (ITV)
was defined as the envelope of all CTVs from the different
respiratory phases and used for treatment planning as the
equivalent of PTV. Treatment planning was performed on
the end-expiration phase.
Plans were optimized aiming to a CTV coverage: V95%
> 90%, (ITV: V90% > 90%) and mean CTV (ITV) dose >50Gy.
For all patients, in addition to the target volume, the entire
liver, the normal liver (whole liver-PTV), the kidneys, the
stomach, the spinal cord were outlined and considered
during optimization. The following explicit planning
objectives were defined: for the total liver V30Gy < 60%,
for the normal liver (liver-ITV), the volume receiving less
than 15Gy was asked to be greater than 700 cm3. For the
stomach V37.5Gy < 5%, for the kidneys: V15Gy < 35%, for the
spinal cord: D1cm
3 < 22Gy.
All patients were treated by VMAT in the form of
RapidArc with 10 MV FFF photon beam generated by a
Varian TrueBeam linear accelerator, which equipped with
the high definition MLC (2.5 mm of leaf resolution at
isocenter in the central 20 cm). Maximum allowed dose
Table 1 Characteristics of the cohort of patients
Characteristics Items N (%)
Sex Female 8/20 (40%)
Male 12/20 (60%)
Age Mean 64.5
Median (range) 68.55 (47–81)
St.dev 11.2
Portal vein thrombosis No 14/20 (65%)
Yes 6/20 (35%)
Tumor location Right lobe 7/22 (32%)
Left lobe 4/22 (18%)
Bilateral lobe 11/22 (50%)




Stage N N0 17/20 (85%)
N1 3/20 (15%)
Stage M M0 17/20 (85%)
M1 3/20 (15%)




Okuda stage I 16/20 (80%)
II 4/20 (20%)




Child-pugh stage A 18 (90%)
B 2 (10%)
Hepatitis No 5 (25%)
B 10 (50%)
C 5 (25%)
B and C 0 (0%)
Initial Alpha-fetoprotein
(ng/mL)
Median (range) 301.4 (2.8 – >52131)
Initial white blood
count (kU/dL)
Median (range) 5.2 (3.3 – 10.7)
Initial haemoglobin
level (g/dL)
Median (range) 12.0 (6.7 – 15.5)
Initial GPT level (U/L) Median (range) 41.5 (18.0 – 244.0)
Initial total bilirubin
level (mg/dL)
Median (range) 0.8 (0.3 – 1.9)
Initial tumor volume (cm3) Median (range) 124 (6 – 848)
Total liver volume (cm3) Median (range) 1343 (928 – 2198)
AJCC: American joint Committee on Cancer, BCLC: Barcelona Clinic Liver
Cancer. HCC: hepatocellular carcinoma. GPT: Glutamic Pyruvic Transaminase.
Values refer to number of patients, % to the total number of 20 patients.
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was performed using single or multiple, coplanar or non-
coplanar, mono-isocentric arcs.
All patients were treated in supine position with arms
placed overhead and were immobilized with individualized
masks and a vacuum cushion for positioning. Delivery was
performed with respiratory gated RapidArc to treat only
the selected respiratory phase (end-expiration with a duty
cycle of 30-70%). Image guidance during treatment was
exploited by means of daily cone-beam CT acquisition to
verify in 3D the proper positioning of patients.
Evaluation
Dosimetric and technical parameters of delivery were
scored including some delivery parameters as well as
standard analysis of dose volume histograms (DVH).
Homogeneity was scored as HI = V5%-V95%)/Dmean as well
as in terms of standard deviation. Paddick Conformity and
Gradient indexes (PCI and PGI) were defined and reported
[17,18]. PCI = TVPIV
2 /(TVPIV x PIV) where TVPIV is the
target volume irradiated at prescription dose and PIV is
the prescribed isodose volume; PGI = V50%PIV/PIV where
V50%PIV is the volume irradiated at 50% of the prescribed
dose. Clinical evaluation was performed after treatment
completion and visits included laboratory assessment and
CT and/or MRI imaging, with reference to baseline condi-
tions determined before start of treatment, during treat-
ment, at 1, 2, 3,6 months after treatment completion, and
then every three-month interval. For basic treatment out-
come was measured in terms of in-field local control.
Tumor response was assessed using modified Response
Evaluation Criteria in Solid Tumors (mRECIST) criteria
for HCC [19]. Local in field recurrence was defined by
new enhancement or progressive disease with CT or MR
imaging during follow-up. RILD was defined as elevated
transaminase of at least two-fold the upper limit of normal
value or pretreatment levels based on the National Cancer
Institute Common Toxicity Criteria for Adverse Events
(CTCAE) version 4.03. Endpoints of gastrointestinal (GI)Table 2 Summary of technical delivery parameters
Items N (%)/Mean ± SD (range)
Number of partial arcs 4.4 ± 0.9 (3–6)
Coplanar arcs Yes: 3 (14%)
No: 19 (86%)
Arc length (deg) 76.6 ± 55.5 (30;240)
MU/Gy 190 ± 46 (136;351)
Dose rate (MU/minute) 1454 ± 382 (922–2400)
BOT (min) 0.7 ± 0.2 (0.4;1.4)
CP area (cm2) 59.5 ± 42.9 (8.2;192.2)
Collimator angle 30.8 ± 12.4 (13;48)
CP = Control Point; BOT = Beam on time, BOT = beam on time, MU = Monito Units.
SD: standard deviation.
Table 3 Summary of the DVH analysis for the CTV and ITV
for the entire cohort of patients
Parameter CTV ITV
Volume (cm3) 131.1 ± 85.2 166.2 ± 200.2
Mean (Gy) 53.8 ± 2.7 53.1 ± 2.3
SD (Gy) 3.3 ± 1.0 3.9 ± 1.1
HI (Gy) 0.19 ± 0.03 0.22 ± 0.05
PCI n.a. 0.98 ± 0.02
PGI n.a. 3.82 ± 0.93
D1% (Gy) 58.7 ± 3.1 58.5 ± 3.4
D99% (Gy) 45.0 ± 3.7 42.7 ± 3.9
V90% (%) 97.6 ± 4.1 94.8 ± 5.4
V95% (%) 93.6 ± 7.7 89.5 ± 10.0
St. Dev: standard deviation; Dx%: dose received by at least x% of the volume;
Vx%: volume receiving at least x% of the dose. HI = homogeneity index,
PCI = Paddick conformity index, PGI = Paddick gradient index, n.a, not applicable.
Data are reported as average values plus or minus standard deviation.
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or ulceration, duodenal hemorrhage or ulceration and
ascites were also scored according to CTCAE 4.03.
Statistical analysis was performed by means of the SPSS
package (version 20, IBM). Survival was determined byTable 4 Summary of the DVH analysis for the organs at risk f
Organ Volume (cm3)
Left kidney 174.2 ± 51.7 (123.2;218.7)
Right kidney 182.3 ± 37.8 (135.8;213.1)
Spine 22.7 ± 7.2 (9.9;35.6)
Stomach 174.8 ± 117.2 (76.3;473.2)
Esophagus 10.3 ± 6.3 (4.8;21.7)
Liver-PTV 1242 ± 330 (780;1981)
(Healthy liver)
V
Total liver 1439 ± 386 (928;2197)
Healthy tissue 20512 ± 5059 (11277;28676)
Dos
Dx%: dose received by at least x% of the volume; Vx%: volume receiving at least x%
Data are reported as average values plus or minus standard deviation and range.Kaplan-Meier methods and reported stratified according
to several variables. Log-rank tests were applied to estimate
significance of differences among survival curves.Results
Patients
A total of 22 liver lesions were treated in the group of 20
patients. Table 1 summarizes the characteristics of the
cohort of patients included in the study. For all patients,
median initial tumor volume was 124 cm3 (ranging from
6 to 848 cm3) corresponding to <10% of the median total
liver volume. Patients presented with uniform distribution
of BCLC (0-A, B or C) or AJCC (I-II, III and IV) stages.
For 3 patients with nodal involvement (1 in porta hepatis,
1 in para-aortic area and 1 in right cardiophrenic angle)
and 3 with distant metastasis (1 in right upper lung, 1 in
right 8th rib, and 1 in peritoneum), the irradiation was lim-
ited to the liver localisaton and and no chemotherapy or
other systemic therapy was combined concurrently. The
vast majority of patients presented with CP stage A (90%);
the majority had no portal vein thrombosis. Hepatitis B
had the most frequent incidence although 25% of patients
had no hepatitis at diagnosis. One patient presented withor the entire cohort of patients
Parameter Mean ± SD Range
Mean (Gy) 1.5 ± 1.3 (0.1;3.3)
D1cm3 (Gy) 3.5 ± 3.1 (0.1;6.9)
V15Gy (%) 0.0 ± 0.0 (0.0;0.0)
Mean (Gy) 2.8 ± 4.1 (0.1;8.8)
D1cm3 (Gy) 10.6 ± 12.3 (0.2;25.1)
V15Gy (%) 4.1 ± 7.2 (0.0;14.8)
D1cm3 (Gy) 8.2 ± 4.5 (1.9;16.7)
Mean (Gy) 4.5 ± 3.0 (3.0;36.6)
D1cm3 (Gy) 9.2 ± 5.8 (0.3;22.4)
V37.5Gy (%) 0.0 ± 0.0 (0.0;0.0)
Mean (Gy) 5.9 ± 7.9 (0.1;19.4)
D1% (Gy) 10.2 ± 9.7 (0.1;30.1)
V50Gy (%) 0.0 ± 0.0 (0.0;0.0)
Mean (Gy) 8.6 ± 4.6 (1.4;17.1)
< 15Gy (cm3) 995.2 ± 163.6 (667.6;1718.2)
V30Gy (%) 24.4 ± 11.6 (0.6;56.4)
Mean (Gy) 13.3 ± 8.3 (2.7;32.9)
V30Gy (%) 13.8 ± 12.1 (1.1;49.3)
Mean (Gy) 2.5 ± 1.7 (0.5;7.3)
V10Gy (%) 6.1 ± 4.6 (0.9;19.5)
eInt (Gy*cm3*104) 6.3 ± 2.7 (0.1;14.2)
of the dose; DoseInt: integral dose.
Figure 2 Average dose volume histograms for CTV, ITV and organs a
one standard deviation.
Figure 1 Isodose distributions for a typical patient in coronal,
sagittal and axial planes. Color-wash threshold was set to 15Gy.
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stages. These patients were treated as discussed for their
primary HCC localisation.Treatment
Table 2 shows the summary of the technical delivery
parameters of the Rapidarc plans. Multiple non-coplanar
arcs were used in 86% of the cases with relatively short
individual arc length (in average <80 degrees per arc). Due
to the use of FFF beams and high dose rates (on average
about 60% of the maximum allowed), the nominal beam
on time (BOT) per fraction resulted very short (<1 minute
in average). The actual time shall be increased, due to
the respiratory gating duty cycle of about 40% resulting
in average of 1.8 minutes.
Table 3 shows results from the dose volume histogram
(DVH) analysis for CTV and ITV; Table 4 reports the same
for the organs at risk (OARs). Figure 1 shows a typical dose
distribution for one patient with the color-wash of dose
distribution set to 15Gy. Figure 2 shows the average doset risk (solid lines). Dashed lines represent inter-patient variability at
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the OARs. Dashed lines represent inter-patient variability
at 1 standard deviation. The coverage requirement on
CTV and ITV was on average respected as well as the
constraint on mean target dose. Conformity resulted
almost optimal (ideal PCI = 1) while, due also to the
relatively large size of the targets, dose gradient was
not pushed at maximum during optimization resulting in
an average value slightly inferior to 4. High target homo-
geneity was on the contrary easily achieved resulting in a
standard deviation to CTV or ITV <8% of the prescription
dose or HI ~ 0.2. The planning objectives for OARs
were in general respected as well. For kidneys, V15Gy
resulted identically 0 in all cases and the average near-
to-maximum dose (D1cm
3 ) ranged from ~3.5Gy for the
contra-lateral organ to ~11Gy for the ipsilateral one. Simi-
larly for the stomach, no patient exceeded the threshold
set to V37.5Gy and the near-to-maximum dose was kept
below 10Gy. D1cm3 to spinal cord resulted ~8Gy, largely
inferior to the objective constraint of 22Gy. V30Gy for totalFigure 3 Kaplan-Meier survival curves for the entire cohort of patient
thrombosis, initial AFP level, AJCC and BCLC stage.liver resulted ~14%, i.e. with a further 46% sparing
compared to the planning objective. Concerning normal
liver (liver-ITV), the volume receiving less than 15Gy
resulted on average near to 1000 cm3 with only one patient
marginally violating the planning objective (668 cm3 instead
of at least 700 cm3).
Response and toxicity
The median follow up was 7.4 months (range: 3–13). Mean
actuarial overall survival was of 9.6 ± 0.9 months (95%C.L.
7.8-11.4 months), median survival was not yet reached.
Figure 3 shows Kaplan-Meier curves for overall survival
for the whole cohort of patients and factorized for some
risk factors. Only initial tumor size and presence of portal
vein thrombosis lead to significant differences in survival.
Initial Alpha-fetoprotein (AFP) level showed a near-to-
significance trend. Complete response was observed in
8/22 (36.4%) lesions; partial response in 7/22 (31.8%),
stable disease in 6/22 (27.3%), 1/22 (4.4%) showed pro-
gression. Figure 4 shows the radiological response fors and stratified according to tumor size, presence of portal vein
Figure 4 The radiological response for two patients at MR at 6 and 3 months after treatment. In both cases, a residual necrotic mass was
detected in the position of the primary HCC without visible enhancing of any viable tumor residual.
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both cases, a residual necrotic mass was detected without
visible enhancing of any viable tumor residual
Alpha-fetoprotein (AFP) level was monitored and its
reduction from baseline before treatment to the end of
radiotherapy and during follow-up resulted highly signifi-
cant for the entire cohort of patients. Figure 5 shows the
reduction of the median nAFP (AFP normalized to the
baseline) over time. At end of therapy, nAFP dropped to
50% of the baseline; at 3 months after treatment comple-
tion n AFP was only 7% of the baseline (p < 0.01 in both
cases). Different trends were observed for the two risk
groups (baseline AFP between normal level to 400 ng/L
versus greater than 400 ng/L). For the first risk group,
AFP remained either stable or presented a mild increase
during treatment and follow-up. The patients belonging
to the highest risk group, showed, on the contrary, the
most remarkable reduction of AFP.No impact was observed on total bilirubin levels between
baseline (0.75 ± 0.40 mg/dL, range: 0.30-1.90) and finding
at 6 months (0.85 ± 0.50 mg/dL, range: 0.50-1.60) and end
of therapy.
A significant (p = 0.01) drop in WBC was observed be-
tween baseline and end of therapy (5.2 ± 2.1 vs 4.4 ± 1.8 U/
dL), this was recovered at 3 months after treatment com-
pletion. No trends were observed for hemoglobin levels.
Concerning treatment toxicity, non-classical RILD, in-
cluding ascites, resulted the most common in 7/20 patients
(35%) with only one case of grade 3. No esophagitis, gastric
hemorrhage or duodenum ulcer was observed. Remaining
toxicities did not exceed the grade 2. GI toxicity is sum-
marized in Table 5.
Discussion
A prospective study was carried out to assess technical
feasibility and basic safety of SBRT for treatment of HCC
Figure 5 The reduction of the median nAFP (AFP normalized to the baseline) over time.
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maximum tolerable dose in early stage patients. For the
current study, a small cohort of patients with different
tumor stages with lesions greater than 5 cm, was enrolled
and treated with RapidArc using FFF beams and high dose
rate. A moderate hypofractionation regimen of 5Gy/frac-
tion was adopted because of the size of primary lesions;
more aggressive scheduling is foreseen for the forthcom-
ing trial. The present study is a feasibility-follow-up of the
previous institutional experience where a cohort of 138
patients were retrospectively analyzed after treatment with
RapidArc with conventional fractionation showing prom-
ising results in terms of local control and survival [10,11].
This investigation demonstrated that hypofractionated
treatments are technically feasible with the possibility
to easily respect planning constraints for OARs and
target volumes. Results demonstrated the possibility to
treat with SBRT these HCC patients using RapidArc
safely and effectively with minimum incidence of acute
toxicity. Local control results are in line with earlier
data. A significant clinical effect at biochemical levelTable 5 Summary of toxicity profiles based on CTCAE
4.03 criteria
Gr 1 Gr 2 Gr 3 Gr 4
RILD 1 (5%) 5 (25%) 1 (5%) 0
Esophagitis 0 0 0 0
Gastric hemorrhage 0 0 0 0
Gastric ulcer 0 2 (10%) 0 0
Gastritis 0 4 (20%) 0 0
Duodenum hemorrhage 0 3 (15%) 0 0
Duodenum ulcer 0 0 0 0
Ascites 2 (10%) 4 (20%) 0 0was observed in the decline of the AFP levels at the
end of treatment and during follow-up.
The optimisation of treatment plans was performed using
most frequently non-coplanar arcs and with this feature,
RapidArc allowed to adequately spare normal liver tissue.
To account for the internal organ motion and to establish
the needed expertise for the future, all deliveries were per-
formed with respiratory gating. RapidArc has been tech-
nically proven to be un-effected by gating [20,21] and in
the present study patients were treated in free breathing
with phase-based gating at end-expiration (breath hold or
deep inspiration are impractical for the patients with huge
HCC and massive ascites). The significant increase in
treatment time due to the low duty cycle (~40%) was
largely compensated by the fast nominal beam on time de-
rived from the RapidArc technique itself and the usage of
FFF beams with a maximum dose rate of 2400MU/mi-
nute. As the study of Scorsetti et al. [22] stated, in practice
the average dose rate reached only ~50% of its potential
suggesting that treatment time will not be an issue also
when higher dose per fractions should be applied. For this
reason, also deep inspiration breath hold might be investi-
gated as well, for at least some subset of patients capable
to cope with it, if associated to FFF beams.Conclusion
Early results in terms of local control and toxicity for
patients treated with RapidArc under moderated SBRT
fractionation regimen, demonstrated the appropriate-
ness of this technique and its feasibility for SBRT in
primary liver cancer. Longer follow-up will allow to con-
solidate these early observations. Dose escalation for early
stage patients will be explored in a separate prospective
trial.
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